Results of ASCEND-4 trial of ceritinib versus chemotherapy in ALK+ NSCLC patients
Gilberto De Castro Jr
Uncovering the genomic landscape of prostate cancer
The risks of combining therapies in renal cell carcinoma and bladder cancer
Recent developments in treatment options for castration-sensitive metastatic prostate cancer
HOPA 2018 updates on urothelial carcinoma: what is new?